Research and Markets has announced the addition of the "Oncology Drug Report - Darzalex - Daratumumab - 2015 analysis; 2016-2021 Expectations" report to their offering.

Darzalex: Big threat to IMD domination of MM market is a comprehensive drug report new monoclonal antibody approved for the indication of multiple myeloma in Nov 2015.

Darzalex is a targeted therapy drug, which falls under the mAb class of drugs. It is indicated for the treatment of second line, third line and beyond multiple myeloma. It is the first monoclo-nal antibody used for treating multiple myeloma.

The report gives basic information about the drug, covering all details from brand name, date of approvals, mechanism of action, molecular structure, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events surrounding the drug, news about Darzalex, information on competitor drugs, litigations, number of clinical trials (by year and by phase), and so on.

The report gives an analysis of the historical quarterly sales (Q4-2015 to Q3-2016) and sales expectations (from 2016-2021). The analysis broadly indicates that the drug took off really well with cumulative sales of this USD 347 mn until date.

Historical quarterly sales analysis: We have shown sales analysis on quarterly basis for the past four quarters from Q4-2015 to Q3-2016. The quarterly data is also in graphical as well as tabular format.

Expected sales analysis: The report has our expectations for Darzalex sales over 2016-2021. We have highlighted the key reasons for our expectations.

Key Topics Covered:

1 About the drug

2. Basic Information

3. Approval timeline infographic (2015, 2016)

4. Regulatory approval details (US, Europe)

5. Historical quarterly sales analysis (Q4-2015 to Q3-2016)

6. Historical quarterly cumulative sales (Q4-2015 to Q3-2016)

7. Q3-2016 update

8. Sales expectations (2016E-2021E)

9. List of key approved drugs for multiple myeloma

10. Endpoint results for drugs in multiple myeloma

11. Event tracker

12. Clinical trials of Darzalex (US)

13. News around Darzalex

14. Annexure

Companies Mentioned

  • Amgen
  • BMS
  • Celgene
  • Genmab
  • Johnson and Johnson
  • Merck & Co.
  • MorPhosys
  • Novartis
  • PharmaMar
  • Roche
  • Sanofi
  • Spectrum
  • Takeda

For more information about this report visit http://www.researchandmarkets.com/research/f92vgd/oncology_drug